Skip to main content
. Author manuscript; available in PMC: 2020 Jul 11.
Published in final edited form as: J Med Chem. 2019 Jun 27;62(13):6262–6275. doi: 10.1021/acs.jmedchem.9b00566

Table 4.

IC50 Values for PeIA Analogs with Single Substitutions of His9, Val10, Glu14, and Leu15 a

α3β2 nAChR
α6/α3β2β3 nAChR
peptide IC50 (nM) n log change in IC50 IC50 (nM) n log change in IC50 selectivity ratio
PeIA 19.4 (15.3–24.6) 5 19.8 (17.9–21.8) 4 1
[His9]PeIA 1.30 (1.19–1.41) 4 −1.2 0.99 (0.93–1.05)12 4 −1.3 1
[Asn9]PeIA 9.32 (8.32–10.4) 6 −0.3 16.0 (12.8–20.0) 4 −0.1 2
[Tyr9]PeIA 9.18 (7.67–11.0) 5 −0.3 13.0 (9.0–18.9) 4 −0.2 1
[Thr9]PeIA 7.10 (5.78–8.72) 5 −0.4 5.12 (4.51–5.81) 4 −0.6 1
[Ala10]PeIA 3.37 (3.05–3.72) 4 −0.8 2.4 (2.0–2.7)12 −0.9 1
[Ile10]PeIA 11.8 (10.2–13.6) 4 −0.2 13.4 (10.9–16.6) 6 −0.2 1
[Leu10]PeIA 10.6 (9.2–12.2) 4 −0.3 18.8 (16.0–22.1)13 0.1 2
[Nle10]PeIA 9.29 (7.99–10.8) 6 −0.3 19.9 (17.3–23.0) 4 0.1 2
[Thr10]PeIA 24.5 (21.7–27.8) 5 0.1 29.0 (23.7–36.2) 4 0.2 1
[Gla14]PeIA 16.6 (15.1–18.4) 4 −0.1 28.5 (25.7–31.6) 4 0.2 2
[Asp14]PeIA 65.1 (44.9–94.4) 4 0.5 21.0 (16.6–26.5) 4 0.1 0.3
[Adi14]PeIA 115 (88.9–148) 4 0.8 29.2 (24.3–35.2) 5 0.2 0.3
[Asu14]PeIA 155 (123–196) 4 0.9 135 (107–171) 4 0.8 1
[Gln14]PeIA 77.1 (57.8–1028) 5 0.6 14.4 (11.7–17.6) 5 −0.1 0.2
[Arg14]PeIA 109 (83.9–141) 4 0.7 7.40 (6.06–9.04) 4 −0.4 0.1
[Arg15]PeIA 161 (133–196) 4 0.9 54.0 (33.1–88.1) 4 0.4 0.3
[Ala15]PeIA 733 (522–1028) 4 1.6 82.5 (63.5–107)13 0.6 0.1
[Val15]PeIA 40.9 (32.8–50.9) 6 0.3 5.20 (4.40–6.14) 4 −0.6 0.1
[Ile15]PeIA 6.41 (5.51–7.46) 4 −0.5 12.8 (10.5–15.5) 5 −0.2 2
[Nle15]PeIA 21.1 (18.5–24.1) 4 0.1 13.2 (10.9–15.9) 5 −0.2 0.6
a

Values in parentheses indicate the 95% CI of the IC50 values. Changes in potency were calculated as the log(analog IC50)/(PeIA IC50), negative values indicate increased potency and positive values indicate decreased potency. Selectivity was calculated as the IC50 ratio of (α6/α3β2β3)/(α3β2).